The FDA has refused Stealth BioTherapeutics’ request to reconsider its application for elamipretide—despite earlier indications from FDA reviewers that such a request was appropriate. Instead, the FDA has instructed Stealth to resubmit under the accelerated approval pathway with a 6-month review timeline, the longer of two options. This delay, coupled with financial constraints facing Stealth, puts the future of elamipretide—and the Expanded Access Program (EAP) through which patients currently receive it—at serious risk. Without immediate action or a shortened review, access could end as soon as September, leaving individuals with Barth syndrome and other mitochondrial diseases without the only treatment shown to improve symptoms.
We are calling on the community to advocate by participating in Elamipretide Action Week and the social media #ShotsForShotsChallenge. We have outlined a week of ways to participate in advocacy from anywhere, from August 18 through 22, to convey the urgency and to keep elamipretide at the forefront. Every voice matters—together, we can push for the urgent action needed to preserve access to this critical therapy.
Make a Meeting Thursday
August 21 is Make a Meeting Thursday
Now’s the time to connect directly with your members of Congress. Send a personalized update to your Congressional representatives and ask to schedule a call.
With Congress in district this week, you may even have the chance to meet your Representative or Senator in person.
Letter template available here.
Take action: Download the letter template, personalize it, and email your Representatives and Senators today to urge swift FDA action on elamipretide.
